1
|
Kerr CP, Grudzinski JJ, Ferreira CA, Adam D, Sheehan-Klenk J, Bates AM, Jin WJ, Kwon O, Jagodinsky JC, Powers M, Sriramaneni RN, Clark PA, Zangl L, Nguyen TPT, Pinchuk AN, Choi C, Massey CF, Hernandez R, Bednarz B, Weichert JP, Morris ZS. Abstract 2828: Impact of sequencing of immune checkpoint blockade and targeted radionuclide therapy on murine tumor response. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-2828] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Background: Sequencing of immune checkpoint inhibitors (ICI) and external beam radiation therapy (EBRT) for cancer treatment has been studied, but the optimal sequencing has yet to be determined. While some studies have noted therapeutic advantages of priming the tumor immune microenvironment with EBRT prior to ICI, others have described the benefit of modulating the tumor infiltrating lymphocyte (TIL) population with ICI before EBRT. Targeted radionuclide therapy (TRT) approaches allow investigation of how irradiation by a tumor-targeted radionuclide and differences in emission type, linear energy transfer, and dose rate affect optimal timing of ICI administration. NM600 is an alkylphosphocholine analog selectively taken up by tumors capable of chelating numerous radionuclides for comparative studies.
Objective: We use two immunologically cold tumor models, MOC2 head and neck squamous cell carcinoma and B78 melanoma, to describe the influence of dose rate on type I interferon (IFN1) signaling and the effect of ICI and 90Y-, 177Lu-, and 225Ac-NM600 TRT sequences on tumor response.
Methods: 90Y, 177Lu, or 225Ac were added to culture media in activities estimated using GEANT4 Monte Carlo to deliver 12 Gy to the cell monolayer. qPCR was performed on cDNA from cells irradiated with EBRT, 90Y, 177Lu, or 225Ac, and harvested on days 1, 3, or 7. In vivo dosimetry was performed using the Monte Carlo-based RAPID platform utilizing serial PET/CT or SPECT/CT imaging and/or longitudinal biodistribution. Differences over time (days 4, 7, 14, 21, 28 after RT) in TIL and systemic immune cell populations were measured by flow cytometry following no treatment, 12 Gy EBRT, or 90Y-, 177Lu-, or 225Ac-NM600 in MOC2 tumors. Mice bearing B78 tumors received 1.5 Gy 90Y-, 177Lu-, or 225Ac-NM600, or no radiation on day 1 +/- ICI (anti-CTLA4 + anti-PDL1) on days -3/0/3 (early), 4/7/10 (middle), or 11/14/17 (late). Mice were monitored for tumor growth and survival.
Results: TRT and EBRT induced IFN1 responses in MOC2 cells. MOC2 cells treated every 24h with EBRT-matched 90Y/225Ac dose rates led to upregulation of IFN1-associated Ifnb1 and Mx1, mimicking radionuclide-induced responses. Increased tumor CD8/Treg ratios and decreased Tregs were observed at day 7 following all RT forms in MOC2 tumors. Long half-life 225Ac-NM600 (90Y: 65h; 177Lu: 161h; 225Ac: 240h) induced similar TIL changes at day 21. For 1.5 Gy 90Y-, 177Lu-, and 225Ac-NM600, B78 tumor growth delay and statistically significant overall survival benefit over respective TRT monotherapy and control groups was observed with early (day -3/0/3) dual ICI administration.
Conclusions: These studies demonstrate novel immunomodulatory effects of α- and β- emitting TRT and the capacity to achieve substantial antitumor responses with appropriate TRT + ICI sequencing. These results may inform clinical trial design of TRT + ICI regimens for patients with metastatic cancers.
Citation Format: Caroline P. Kerr, Joseph J. Grudzinski, Carolina A. Ferreira, David Adam, Julia Sheehan-Klenk, Amber M. Bates, Won Jong Jin, Ohyun Kwon, Justin C. Jagodinsky, Maria Powers, Raghava N. Sriramaneni, Paul A. Clark, Luke Zangl, Thanh Phuong T. Nguyen, Anatoly N. Pinchuk, Cynthia Choi, Christopher F. Massey, Reinier Hernandez, Bryan Bednarz, Jamey P. Weichert, Zachary S. Morris. Impact of sequencing of immune checkpoint blockade and targeted radionuclide therapy on murine tumor response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2828.
Collapse
Affiliation(s)
| | | | | | - David Adam
- 1University of Wisconsin-Madison, Madison, WI
| | | | | | | | - Ohyun Kwon
- 1University of Wisconsin-Madison, Madison, WI
| | | | | | | | | | - Luke Zangl
- 1University of Wisconsin-Madison, Madison, WI
| | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Nguyen TPT, Kerr CP, Grudzinski JJ, Ferreira CA, Sheehan-Klenk J, Kwon O, Powers M, Clark PA, Sriramaneni RN, Hernandez R, Bednarz B, Weichert JP, Morris ZS. Abstract 6407: Radionuclide-specific effects of90Y-,177Lu-, or225Ac-NM600 targeted radionuclide therapy on tumor immunomodulation and enhanced immunotherapy response in syngeneic murine tumors. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-6407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Background: Targeted radionuclide therapy (TRT) delivers radiation treatment systemically to tumor sites via a therapeutic radionuclide-linked tumor-selective targeting vector. NM600 is an alkylphosphocholine analog selectively taken up and retained in murine and human tumor cells. We previously showed that low dose radiation delivery with 90Y-NM600 improves tumor response to immune checkpoint inhibitors (ICIs). Understanding the effect of different radionuclide physical properties (emission type, linear energy transfer (LET), half-life, and tissue range) on immunomodulation of metastatic cancers may guide therapy development. Here, we evaluated the type 1 interferon (IFN1) response elicited by 90Y-, 177Lu-, and 225Ac-NM600 in an immunologically cold syngeneic murine tumor model, B78 melanoma. We hypothesized that the unique physical properties of radionuclides will differentially impact immunomodulation by TRT.
Methods: Mice bearing B78 WT or Tmem173 -/- CRISPR deletion B78 (STING KO) tumors were randomized to receive 1.5 Gy external beam radiation (EBRT), an equivalent tumor dose of 90Y-, 177Lu-, or 225Ac-NM600 determined by the Monte Carlo-based RAPID platform, or no radiation on day 1. Tumors were harvested on days 4, 7, and 10 for RT-qPCR. Mice bearing two B78 WT or Tmem173 -/- CRISPR deletion B78 (STING KO) tumors were randomized to receive 4 Gy external beam radiation therapy (EBRT), an equivalent tumor dose of 90Y- or 177Lu-NM600, 0.5 μCi 225Ac-NM600, or no radiation +/- dual ICI (anti-CTLA4 and anti-PDL1). Mice were monitored for tumor growth and survival following these treatments.
Results: Both EBRT and TRT upregulated expression of IFN1 response-associated genes (Ifnβ1, Mx1) in B78 WT tumors. Only TRT induced upregulation of Ifnβ1 and Mx1 in STING KO B78 tumors. Ddx58, which encodes RIG-I, integral to an alternative IFN1 pathway, was upregulated in both B78 WT and STING KO tumors following 225Ac-NM600, but not other treatments. TRT in B78 STING KO tumors had earlier expression of IFN1 response-associated genes than B78 WT, 225Ac-NM600 in combination with dual ICI improved overall survival over 90Y- or 177Lu-NM600 + ICI and 225Ac-NM600 monotherapy.
Conclusions: The distinct physical properties of TRT radiation, γ, β or α, affect the timing, magnitude, and molecular pathways leading to this IFN1 response. Understanding TRT effects on the tumor microenvironment may optimize TRT and immunotherapy.
Citation Format: Thanh Phuong T. Nguyen, Caroline P. Kerr, Joseph J. Grudzinski, Carolina A. Ferreira, Julia Sheehan-Klenk, Ohyun Kwon, Maria Powers, Paul A. Clark, Raghava N. Sriramaneni, Reinier Hernandez, Bryan Bednarz, Jamey P. Weichert, Zachary S. Morris. Radionuclide-specific effects of90Y-,177Lu-, or225Ac-NM600 targeted radionuclide therapy on tumor immunomodulation and enhanced immunotherapy response in syngeneic murine tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6407.
Collapse
Affiliation(s)
| | | | | | | | | | - Ohyun Kwon
- 1University of Wisconsin - Madison, Madison, WI
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Kostka L, Kotrchová L, Randárová E, Ferreira CA, Malátová I, Lee HJ, Olson AP, Engle JW, Kovář M, Cai W, Šírová M, Etrych T. Evaluation of linear versus star-like polymer anti-cancer nanomedicines in mouse models. J Control Release 2023; 353:549-562. [PMID: 36470330 PMCID: PMC9892306 DOI: 10.1016/j.jconrel.2022.11.060] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Revised: 11/25/2022] [Accepted: 11/30/2022] [Indexed: 12/14/2022]
Abstract
Nanomedicines are considered next generation therapeutics with advanced therapeutic properties and reduced side effects. Herein, we introduce tailored linear and star-like water-soluble nanosystems as stimuli-sensitive nanomedicines for the treatment of solid tumors or hematological malignancies. The polymer carrier and drug pharmacokinetics were independently evaluated to elucidate the relationship between the nanosystem structure and its distribution in the body. Positron emission tomography and optical imaging demonstrated enhanced tumor accumulation of the polymer carriers in 4T1-bearing mice with increased tumor-to-blood and tumor-to-muscle ratios. Additionally, there was a significant accumulation of doxorubicin bound to various polymer carriers in EL4 tumors, as well as excellent in vivo therapeutic activity in EL4 lymphoma and moderate efficacy in 4T1 breast carcinoma. The linear nanomedicine showed at least comparable pharmacologic properties to the star-like nanomedicines regarding doxorubicin transport. Therefore, if multiple parameters are considered such as its optimized structure and simple and reproducible synthesis, this polymer carrier system is the most promising for further preclinical and clinical investigations.
Collapse
Affiliation(s)
- Libor Kostka
- Institute of Macromolecular Chemistry CAS, Department of Biomedical Polymers, Heyrovského nám. 2, Prague 6 16206, Czech Republic
| | - Lenka Kotrchová
- Institute of Macromolecular Chemistry CAS, Department of Biomedical Polymers, Heyrovského nám. 2, Prague 6 16206, Czech Republic
| | - Eva Randárová
- Institute of Macromolecular Chemistry CAS, Department of Biomedical Polymers, Heyrovského nám. 2, Prague 6 16206, Czech Republic
| | - Carolina A Ferreira
- Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, United States
| | - Iva Malátová
- Institute of Microbiology CAS, Laboratory of Tumor Immunology, Vídeňská 1083, Prague 4 14220, Czech Republic
| | - Hye Jin Lee
- Department of Pharmaceutical Sciences, University of Wisconsin-Madison, Madison, WI, United States
| | - Aeli P Olson
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, United States
| | - Jonathan W Engle
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, United States
| | - Marek Kovář
- Institute of Microbiology CAS, Laboratory of Tumor Immunology, Vídeňská 1083, Prague 4 14220, Czech Republic
| | - Weibo Cai
- Department of Pharmaceutical Sciences, University of Wisconsin-Madison, Madison, WI, United States; Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, United States
| | - Milada Šírová
- Institute of Microbiology CAS, Laboratory of Tumor Immunology, Vídeňská 1083, Prague 4 14220, Czech Republic
| | - Tomáš Etrych
- Institute of Macromolecular Chemistry CAS, Department of Biomedical Polymers, Heyrovského nám. 2, Prague 6 16206, Czech Republic.
| |
Collapse
|
4
|
Potluri HK, Ferreira CA, Grudzinski J, Massey C, Aluicio-Sarduy E, Engle JW, Kwon O, Marsh IR, Bednarz BP, Hernandez R, Weichert JP, McNeel DG. Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors. J Immunother Cancer 2022; 10:jitc-2022-005060. [PMID: 36002185 PMCID: PMC9413196 DOI: 10.1136/jitc-2022-005060] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/23/2022] [Indexed: 12/14/2022] Open
Abstract
Background Systemic radiation treatments that preferentially irradiate cancer cells over normal tissue, known as targeted radionuclide therapy (TRT), have shown significant potential for treating metastatic prostate cancer. Preclinical studies have demonstrated the ability of external beam radiation therapy (EBRT) to sensitize tumors to T cell checkpoint blockade. Combining TRT approaches with immunotherapy may be more feasible than combining with EBRT to treat widely metastatic disease, however the effects of TRT on the prostate tumor microenvironment alone and in combinfation with checkpoint blockade have not yet been studied. Methods C57BL/6 mice-bearing TRAMP-C1 tumors and FVB/NJ mice-bearing Myc-CaP tumors were treated with a single intravenous administration of either low-dose or high-dose 90Y-NM600 TRT, and with or without anti-PD-1 therapy. Groups of mice were followed for tumor growth while others were used for tissue collection and immunophenotyping of the tumors via flow cytometry. Results 90Y-NM600 TRT was safe at doses that elicited a moderate antitumor response. TRT had multiple effects on the tumor microenvironment including increasing CD8 +T cell infiltration, increasing checkpoint molecule expression on CD8 +T cells, and increasing PD-L1 expression on myeloid cells. However, PD-1 blockade with TRT treatment did not improve antitumor efficacy. Tregs remained functional up to 1 week following TRT, but CD8 +T cells were not, and the suppressive function of Tregs increased when anti-PD-1 was present in in vitro studies. The combination of anti-PD-1 and TRT was only effective in vivo when Tregs were depleted. Conclusions Our data suggest that the combination of 90Y-NM600 TRT and PD-1 blockade therapy is ineffective in these prostate cancer models due to the activating effect of anti-PD-1 on Tregs. This finding underscores the importance of thorough understanding of the effects of TRT and immunotherapy combinations on the tumor immune microenvironment prior to clinical investigation.
Collapse
Affiliation(s)
- Hemanth K Potluri
- University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Carolina A Ferreira
- University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.,Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Joseph Grudzinski
- University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.,Radiology, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Christopher Massey
- University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.,Radiology, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | | | - Jonathan W Engle
- Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA.,Radiology, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Ohyun Kwon
- University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.,Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Ian R Marsh
- University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.,Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA.,Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland, USA
| | - Bryan P Bednarz
- University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.,Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Reinier Hernandez
- University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.,Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Jamey P Weichert
- University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.,Radiology, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Douglas G McNeel
- University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA
| |
Collapse
|
5
|
Rosenkrans ZT, Massey CF, Bernau K, Ferreira CA, Jeffery JJ, Schulte JJ, Moore M, Valla F, Batterton JM, Drake CR, McMillan AB, Sandbo N, Pirasteh A, Hernandez R. [ 68 Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity. Eur J Nucl Med Mol Imaging 2022; 49:3705-3716. [PMID: 35556159 DOI: 10.1007/s00259-022-05814-9] [Citation(s) in RCA: 23] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2021] [Accepted: 04/23/2022] [Indexed: 12/21/2022]
Abstract
PURPOSE The lack of effective molecular biomarkers to monitor idiopathic pulmonary fibrosis (IPF) activity or treatment response remains an unmet clinical need. Herein, we determined the utility of fibroblast activation protein inhibitor for positron emission tomography (FAPI PET) imaging in a mouse model of pulmonary fibrosis. METHODS Pulmonary fibrosis was induced by intratracheal administration of bleomycin (1 U/kg) while intratracheal saline was administered to control mice. Subgroups from each cohort (n = 3-5) underwent dynamic 1 h PET/CT after intravenously injecting FAPI-46 radiolabeled with gallium-68 ([68 Ga]Ga-FAPI-46) at 7 days and 14 days following disease induction. Animals were sacrificed following imaging for ex vivo gamma counting and histologic correlation. [68 Ga]Ga-FAPI-46 uptake was quantified and reported as percent injected activity per cc (%IA/cc) or percent injected activity (%IA). Lung CT density in Hounsfield units (HU) was also correlated with histologic examinations of lung fibrosis. RESULTS CT only detected differences in the fibrotic response at 14 days post-bleomycin administration. [68 Ga]Ga-FAPI-46 lung uptake was significantly higher in the bleomycin group than in control subjects at 7 days and 14 days. Significantly (P = 0.0012) increased [68 Ga]Ga-FAPI-46 lung uptake in the bleomycin groups at 14 days (1.01 ± 0.12%IA/cc) vs. 7 days (0.33 ± 0.09%IA/cc) at 60 min post-injection of the tracer was observed. These findings were consistent with an increase in both fibrinogenesis and FAP expression as seen in histology. CONCLUSION CT was unable to assess disease activity in a murine model of IPF. Conversely, FAPI PET detected both the presence and activity of lung fibrogenesis, making it a promising tool for assessing early disease activity and evaluating the efficacy of therapeutic interventions in lung fibrosis patients.
Collapse
Affiliation(s)
- Zachary T Rosenkrans
- Department of Medical Physics, University of Wisconsin-Madison, 1111 Highland Ave., Room 7137, WI, 53705, Madison, USA
| | - Christopher F Massey
- Department of Medical Physics, University of Wisconsin-Madison, 1111 Highland Ave., Room 7137, WI, 53705, Madison, USA
| | - Ksenija Bernau
- Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA
| | - Carolina A Ferreira
- Department of Medical Physics, University of Wisconsin-Madison, 1111 Highland Ave., Room 7137, WI, 53705, Madison, USA
| | - Justin J Jeffery
- University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA
| | - Jefree J Schulte
- Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA
| | | | | | - Jeanine M Batterton
- Department of Medical Physics, University of Wisconsin-Madison, 1111 Highland Ave., Room 7137, WI, 53705, Madison, USA
| | | | - Alan B McMillan
- Department of Medical Physics, University of Wisconsin-Madison, 1111 Highland Ave., Room 7137, WI, 53705, Madison, USA
| | - Nathan Sandbo
- Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA
| | - Ali Pirasteh
- Department of Medical Physics, University of Wisconsin-Madison, 1111 Highland Ave., Room 7137, WI, 53705, Madison, USA.
- Department of Radiology, University of Wisconsin-Madison, 1111 Highland Ave., Room 2423, WI, 53705, Madison, USA.
| | - Reinier Hernandez
- Department of Medical Physics, University of Wisconsin-Madison, 1111 Highland Ave., Room 7137, WI, 53705, Madison, USA.
- University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA.
- Department of Radiology, University of Wisconsin-Madison, 1111 Highland Ave., Room 2423, WI, 53705, Madison, USA.
| |
Collapse
|
6
|
Ferreira CA. Voices in Molecular Pharmaceutics: Meet Dr. Carolina Ferreira, Who Is Developing the Next Generation of Radioactive Theranostics. Mol Pharm 2021; 18:4235-4236. [PMID: 34865495 DOI: 10.1021/acs.molpharmaceut.1c00835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Ferreira CA, Heidari P, Ataeinia B, Sinevici N, Sise ME, Colvin RB, Wehrenberg-Klee E, Mahmood U. Non-invasive Detection of Immunotherapy-Induced Adverse Events. Clin Cancer Res 2021; 27:5353-5364. [PMID: 34253581 DOI: 10.1158/1078-0432.ccr-20-4641] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Revised: 01/27/2021] [Accepted: 07/08/2021] [Indexed: 11/16/2022]
Abstract
PURPOSE Cancer immunotherapy has markedly improved the prognosis of patients with a broad variety of malignancies. However, benefits are weighed against unique toxicities, with immune-related adverse events (irAE) that are frequent and potentially life-threatening. The diagnosis and management of these events are challenging due to heterogeneity of timing onset, multiplicity of affected organs, and lack of non-invasive monitoring techniques. We demonstrate the use of a granzyme B-targeted PET imaging agent (GZP) for irAE identification in a murine model. EXPERIMENTAL DESIGN We generated a model of immunotherapy-induced adverse events in Foxp3-DTR-GFP mice bearing MC38 tumors. GZP PET imaging was performed to evaluate organs non-invasively. We validated imaging with ex vivo analysis, correlating the establishment of these events with the presence of immune infiltrates and granzyme B upregulation in tissue. To demonstrate the clinical relevance of our findings, the presence of granzyme B was identified through immunofluorescence staining in tissue samples of patients with confirmed checkpoint inhibitor-associated adverse events. RESULTS GZP PET imaging revealed differential uptake in organs affected by irAEs, such as colon, spleen, and kidney, which significantly diminished after administration of the immunosuppressor dexamethasone. The presence of granzyme B and immune infiltrates were confirmed histologically and correlated with significantly higher uptake in PET imaging. The presence of granzyme B was also confirmed in samples from patients that presented with clinical irAEs. CONCLUSIONS We demonstrate an interconnection between the establishment of irAEs and granzyme B presence and, for the first time, the visualization of those events through PET imaging.
Collapse
Affiliation(s)
- Carolina A Ferreira
- Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts
| | - Pedram Heidari
- Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts
| | - Bahar Ataeinia
- Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts
| | - Nicoleta Sinevici
- Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts
| | - Meghan E Sise
- Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
| | - Robert B Colvin
- Department of Pathology and Medicine, Massachusetts General Hospital, Boston, Massachusetts
| | | | - Umar Mahmood
- Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
| |
Collapse
|
8
|
Ferreira CA, Goel S, Ehlerding EB, Rosenkrans ZT, Jiang D, Sun T, Aluicio-Sarduy E, Engle JW, Ni D, Cai W. Ultrasmall Porous Silica Nanoparticles with Enhanced Pharmacokinetics for Cancer Theranostics. Nano Lett 2021; 21:4692-4699. [PMID: 34029471 PMCID: PMC8265214 DOI: 10.1021/acs.nanolett.1c00895] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Theranostic nanoparticles hold the potential to greatly improve cancer management by providing personalized medicine. Although many theranostic nanoconstructs have been successful in preclinical studies, clinical translation is still hampered by their limited targeting capability and lack of successful therapeutic efficacy. We report the use of novel ultrasmall porous silica nanoparticles (UPSN) with enhanced in vivo pharmacokinetics such as high target tissue accumulation (12% ID/g in the tumor) and evasion from the reticuloendothelial system (RES) organs. Herein, UPSN is conjugated with the isotopic pair 90/86Y, enabling both noninvasive imaging as well as internal radiotherapy. In vivo PET imaging demonstrates prolonged blood circulation and excellent tumor contrast with 86Y-DOTA-UPSN. Tumor-to-muscle and tumor-to-liver uptake values were significantly high (12.4 ± 1.7 and 1.5 ± 0.5, respectively), unprecedented for inorganic nanomaterials. 90Y-DOTA-UPSN significantly inhibits tumor growth and increases overall survival, indicating the promise of UPSN for future clinical translation as a cancer theranostic agent.
Collapse
|
9
|
Kang L, Li C, Rosenkrans ZT, Huo N, Chen Z, Ehlerding EB, Huo Y, Ferreira CA, Barnhart TE, Engle JW, Wang R, Jiang D, Xu X, Cai W. CD38-Targeted Theranostics of Lymphoma with 89Zr/ 177Lu-Labeled Daratumumab. Adv Sci (Weinh) 2021; 8:2001879. [PMID: 34026426 PMCID: PMC8132161 DOI: 10.1002/advs.202001879] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Revised: 12/30/2020] [Indexed: 05/05/2023]
Abstract
Lymphoma is a heterogeneous disease with varying clinical manifestations and outcomes. Many subtypes of lymphoma, such as Burkitt's lymphoma and diffuse large B cell lymphoma, are highly aggressive with dismal prognosis even after conventional chemotherapy and radiotherapy. As such, exploring specific biomarkers for lymphoma is of high clinical significance. Herein, a potential marker, CD38, is investigated for differentiating lymphoma. A CD38-targeting monoclonal antibody (mAb, daratumumab) is then radiolabeled with Zr-89 and Lu-177 for theranostic applications. As the diagnostic component, the Zr-89-labeled mAb is highly specific in delineating CD38-positive lymphoma via positron emission tomography (PET) imaging, while the Lu-177-labeled mAb serves well as the therapeutic component to suppress tumor growth after a one-time administration. These results strongly suggest that CD38 is a lymphoma-specific marker and prove that 89Zr/177Lu-labeled daratumumab facilitates immunoPET imaging and radioimmunotherapy of lymphoma in preclinical models. Further clinical evaluation and translation of this CD38-targeted theranostics may be of significant help in lymphoma patient stratification and management.
Collapse
MESH Headings
- ADP-ribosyl Cyclase 1/immunology
- ADP-ribosyl Cyclase 1/metabolism
- Animals
- Antibodies, Monoclonal/pharmacokinetics
- Antibodies, Monoclonal/pharmacology
- Cell Line, Tumor
- Humans
- Immunologic Factors/pharmacokinetics
- Lutetium/pharmacokinetics
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Lymphoma, Large B-Cell, Diffuse/immunology
- Lymphoma, Large B-Cell, Diffuse/pathology
- Membrane Glycoproteins/immunology
- Membrane Glycoproteins/metabolism
- Mice, Inbred BALB C
- Mice, SCID
- Positron Emission Tomography Computed Tomography/methods
- Precision Medicine/methods
- Radioisotopes/pharmacokinetics
- Radiopharmaceuticals/pharmacokinetics
- Radiopharmaceuticals/pharmacology
- Tissue Distribution
- Xenograft Model Antitumor Assays
- Zirconium/pharmacokinetics
- Mice
Collapse
Affiliation(s)
- Lei Kang
- Department of Nuclear MedicinePeking University First HospitalBeijing100034China
- Departments of Radiology and Medical PhysicsUniversity of Wisconsin – MadisonMadisonWI53705USA
| | - Cuicui Li
- Department of Nuclear MedicinePeking University First HospitalBeijing100034China
| | - Zachary T. Rosenkrans
- Department of Pharmaceutical SciencesUniversity of Wisconsin – MadisonMadisonWI53705USA
| | - Nan Huo
- Department of Medical Molecular BiologyBeijing Institute of BiotechnologyBeijing100850China
| | - Zhao Chen
- Department of Nuclear MedicinePeking University First HospitalBeijing100034China
| | - Emily B. Ehlerding
- Departments of Radiology and Medical PhysicsUniversity of Wisconsin – MadisonMadisonWI53705USA
| | - Yan Huo
- Department of Nuclear MedicinePeking University First HospitalBeijing100034China
| | - Carolina A. Ferreira
- Departments of Radiology and Medical PhysicsUniversity of Wisconsin – MadisonMadisonWI53705USA
| | - Todd E. Barnhart
- Departments of Radiology and Medical PhysicsUniversity of Wisconsin – MadisonMadisonWI53705USA
| | - Jonathan W. Engle
- Departments of Radiology and Medical PhysicsUniversity of Wisconsin – MadisonMadisonWI53705USA
| | - Rongfu Wang
- Department of Nuclear MedicinePeking University First HospitalBeijing100034China
| | - Dawei Jiang
- Departments of Radiology and Medical PhysicsUniversity of Wisconsin – MadisonMadisonWI53705USA
- Department of Nuclear MedicineUnion HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan430022China
| | - Xiaojie Xu
- Department of Medical Molecular BiologyBeijing Institute of BiotechnologyBeijing100850China
| | - Weibo Cai
- Departments of Radiology and Medical PhysicsUniversity of Wisconsin – MadisonMadisonWI53705USA
- Department of Pharmaceutical SciencesUniversity of Wisconsin – MadisonMadisonWI53705USA
| |
Collapse
|
10
|
Ferreira CA, Kang L, Li C, Kamkaew A, Barrett KE, Aluicio-Sarduy E, Yang Y, Engle JW, Jiang D, Cai W. ImmunoPET of the differential expression of CD146 in breast cancer. Am J Cancer Res 2021; 11:1586-1599. [PMID: 33948375 PMCID: PMC8085863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2020] [Accepted: 01/20/2021] [Indexed: 06/12/2023] Open
Abstract
With advancement in antibody engineering, the development and characterization of new cancer-specific molecular targets are in the forefront of this PET-antibody combination "revolution". Overexpression of CD146 in different types of tumors, including breast tumor, has been associated with tumor progression and poor prognosis. Non-invasive detection of CD146 with a monoclonal antibody may provide a noninvasive diagnostic tool with high specificity and accountability. METHODS Herein, we have developed a CD146-specific monoclonal antibody (YY146), radiolabeled it with 52Mn and 89Zr and identified its capability in acting as a non-invasive imaging agent that specific targets CD146 in different murine breast cancer models. CD146 expression was first screened in different breast tumor cell lines through Western Blot and confirmed its binding ability to YY146 using Flow Cytometry. Serial immunoPET images were carried out after intravenous administration of 52Mn or 89Zr labeled YY146. In addition, we also performed in vivo fluorescence imaging in animals injected with YY146 conjugated with Cy5.5. RESULTS Western Blot results show that MDA-MB-435 cell line had greater levels of CD146 expression when compared to the other cell lines investigated. Flow cytometry confirmed binding ability of YY146. PET images revealed well correlated uptake between tumor uptake and CD146 expression levels, confirmed by biodistribution studies and fluorescence imaging. CONCLUSION PET imaging, for up to 7 days, of mice bearing three different breast tumors were carried out and revealed radiotracer uptake in tumors that strongly (r2 = 0.98, P < 0.01), correlated with CD146 expression levels, as confirmed by in vitro and ex vivo studies.
Collapse
Affiliation(s)
- Carolina A Ferreira
- Department of Biomedical Engineering, University of Wisconsin-MadisonMadison, WI, USA
| | - Lei Kang
- Department of Nuclear Medicine, Peking University First HospitalBeijing, China
- Department of Radiology and Medical Physics, University of Wisconsin-MadisonWI, USA
| | - Cuicui Li
- Department of Nuclear Medicine, Peking University First HospitalBeijing, China
| | - Anyanee Kamkaew
- Department of Radiology and Medical Physics, University of Wisconsin-MadisonWI, USA
| | - Kendall E Barrett
- Department of Radiology and Medical Physics, University of Wisconsin-MadisonWI, USA
| | | | - Yunan Yang
- Department of Radiology and Medical Physics, University of Wisconsin-MadisonWI, USA
| | - Jonathan W Engle
- Department of Radiology and Medical Physics, University of Wisconsin-MadisonWI, USA
| | - Dawei Jiang
- Department of Radiology and Medical Physics, University of Wisconsin-MadisonWI, USA
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, China
| | - Weibo Cai
- Department of Biomedical Engineering, University of Wisconsin-MadisonMadison, WI, USA
- Department of Radiology and Medical Physics, University of Wisconsin-MadisonWI, USA
| |
Collapse
|
11
|
Rosenkrans ZT, Ferreira CA, Ni D, Cai W. Internally Responsive Nanomaterials for Activatable Multimodal Imaging of Cancer. Adv Healthc Mater 2021; 10:e2000690. [PMID: 32691969 PMCID: PMC7855763 DOI: 10.1002/adhm.202000690] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2020] [Revised: 06/03/2020] [Indexed: 12/13/2022]
Abstract
Advances in technology and nanomedicine have led to the development of nanoparticles that can be activated for multimodal imaging of cancer, where a stimulus induces a material modification that enhances image contrast. Multimodal imaging using nanomaterials with this capability can combine the advantages and overcome the limitations of any single imaging modality. When designed with stimuli-responsive abilities, the target-to-background ratio of multimodal imaging nanoprobes increases because specific stimuli in the tumor enhance the signal. Several aspects of the tumor microenvironment can be exploited as an internal stimulus response for multimodal imaging applications, such as the pH gradient, redox processes, overproduction of various enzymes, or combinations of these. In this review, design strategies are discussed and an overview of the recent developments of internally responsive multimodal nanomaterials is provided. Properly implementing this approach improves noninvasive cancer diagnosis and staging as well as provides a method to monitor drug delivery and treatment response.
Collapse
Affiliation(s)
- Zachary T Rosenkrans
- Department of Pharmaceutical Sciences, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Carolina A Ferreira
- Department of Radiology and Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Dalong Ni
- Department of Radiology and Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Weibo Cai
- Department of Pharmaceutical Sciences, University of Wisconsin-Madison, Madison, WI, 53705, USA
- Department of Radiology and Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
| |
Collapse
|
12
|
Li C, Kang L, Fan K, Ferreira CA, Becker KV, Huo N, Liu H, Yang Y, Engle JW, Wang R, Xu X, Jiang D, Cai W. ImmunoPET of CD146 in Orthotopic and Metastatic Breast Cancer Models. Bioconjug Chem 2021; 32:1306-1314. [PMID: 33475350 DOI: 10.1021/acs.bioconjchem.0c00649] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
The overexpression of CD146 in breast cancer is considered a hallmark of tumor progression and metastasis, particularly in triple negative breast cancer. Aimed at imaging differential CD146 expressions in breast cancer, a noninvasive method for predictive prognosis and diagnosis was investigated using a 64Cu-labeled CD146-specific monoclonal antibody, YY146. CD146 expression was screened in human breast cancer cell lines using Western blotting. Binding ability was evaluated using flow cytometry and immunofluorescent staining. YY146 was conjugated with 1,4,7-triazacyclononane-triacetic acid (NOTA) and radiolabeled with 64Cu following standard procedures. Serial PET or PET/CT imaging was performed in orthotopic and metastatic breast cancer tumor models. Biodistribution was performed after the final time point of imaging. Finally, tissue immunofluorescent staining and hematoxylin and eosin (H&E) staining were performed on tumor tissues. The MDA-MB-435 cell line showed the highest CD146 expression level, whereas MCF-7 had the lowest level at the cellular level. ImmunoPET showed that MDA-MB-435 orthotopic tumors had high and clear radioactive accumulation after the administration of 64Cu-NOTA-YY146. The tumor uptake of 64Cu-NOTA-YY146 in MDA-MB-435 was significantly higher than that in MCF-7 and nonspecific IgG control groups (P < 0.01). Biodistribution verified the PET imaging results. For metastatic models, 64Cu-NOTA-YY146 allowed for the visualization of high radioactivity accumulation in metastatic MDA-MB-435 tumors, which was confirmed by ex vivo biodistribution of lung tissues. H&E staining proved the successful building of metastatic tumor models. Immunofluorescent staining verified the differential expression of CD146 in orthotopic tumors. Therefore, 64Cu-NOTA-YY146 could be used as an immunoPET probe to visualize CD146 in the breast cancer model and is potentially useful for cancer diagnosis, prognosis prediction, and monitoring therapeutic response.
Collapse
Affiliation(s)
- Cuicui Li
- Department of Nuclear Medicine, Peking University First Hospital, Beijing, China 100034
| | - Lei Kang
- Department of Nuclear Medicine, Peking University First Hospital, Beijing, China 100034.,Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Kevin Fan
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Carolina A Ferreira
- Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Kaelyn V Becker
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Nan Huo
- Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing, China 100850
| | - Hanxiao Liu
- Department of Oncology, Harbin Medical University Affiliated Cancer Hospital, Harbin, China 150081
| | - Yunan Yang
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Jonathan W Engle
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Rongfu Wang
- Department of Nuclear Medicine, Peking University First Hospital, Beijing, China 100034
| | - Xiaojie Xu
- Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing, China 100850
| | - Dawei Jiang
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.,Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 430022
| | - Weibo Cai
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.,Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| |
Collapse
|
13
|
Rosenkrans ZT, Sun T, Jiang D, Chen W, Barnhart TE, Zhang Z, Ferreira CA, Wang X, Engle JW, Huang P, Cai W. Selenium-Doped Carbon Quantum Dots Act as Broad-Spectrum Antioxidants for Acute Kidney Injury Management. Adv Sci (Weinh) 2020; 7:2000420. [PMID: 32596126 PMCID: PMC7312409 DOI: 10.1002/advs.202000420] [Citation(s) in RCA: 76] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/05/2020] [Revised: 03/06/2020] [Indexed: 05/06/2023]
Abstract
The manifestation of acute kidney injury (AKI) is associated with poor patient outcomes, with treatment options limited to hydration or renal replacement therapies. The onset of AKI is often associated with a surfeit of reactive oxygen species. Here, it is shown that selenium-doped carbon quantum dots (SeCQDs) have broad-spectrum antioxidant properties and prominent renal accumulation in both healthy and AKI mice. Due to these properties, SeCQDs treat or prevent two clinically relevant cases of AKI induced in murine models by either rhabdomyolysis or cisplatin using only 1 or 50 µg per mouse, respectively. The attenuation of AKI in both models is confirmed by blood serum measurements, kidney tissue staining, and relevant biomarkers. The therapeutic efficacy of SeCQDs exceeds amifostine, a drug approved by the Food and Drug Administration that also acts by scavenging free radicals. The findings indicate that SeCQDs show great potential as a treatment option for AKI and possibly other ROS-related diseases.
Collapse
Affiliation(s)
- Zachary T. Rosenkrans
- Department of Pharmaceutical SciencesUniversity of Wisconsin‐MadisonMadisonWI53705USA
| | - Tuanwei Sun
- Marshall Laboratory of Biomedical EngineeringInternational Cancer CenterLaboratory of Evolutionary TheranosticsSchool of Biomedical EngineeringShenzhen University Health Science CenterShenzhen518060China
- Departments of Radiology and Medical PhysicsUniversity of Wisconsin‐MadisonMadisonWI53705USA
| | - Dawei Jiang
- Marshall Laboratory of Biomedical EngineeringInternational Cancer CenterLaboratory of Evolutionary TheranosticsSchool of Biomedical EngineeringShenzhen University Health Science CenterShenzhen518060China
- Departments of Radiology and Medical PhysicsUniversity of Wisconsin‐MadisonMadisonWI53705USA
| | - Weiyu Chen
- Departments of Radiology and Medical PhysicsUniversity of Wisconsin‐MadisonMadisonWI53705USA
| | - Todd E. Barnhart
- Departments of Radiology and Medical PhysicsUniversity of Wisconsin‐MadisonMadisonWI53705USA
| | - Ziyi Zhang
- Department of Materials Science and EngineeringUniversity of Wisconsin‐MadisonMadisonWI53705USA
| | - Carolina A. Ferreira
- Departments of Radiology and Medical PhysicsUniversity of Wisconsin‐MadisonMadisonWI53705USA
| | - Xudong Wang
- Department of Materials Science and EngineeringUniversity of Wisconsin‐MadisonMadisonWI53705USA
| | - Jonathan W. Engle
- Departments of Radiology and Medical PhysicsUniversity of Wisconsin‐MadisonMadisonWI53705USA
| | - Peng Huang
- Marshall Laboratory of Biomedical EngineeringInternational Cancer CenterLaboratory of Evolutionary TheranosticsSchool of Biomedical EngineeringShenzhen University Health Science CenterShenzhen518060China
| | - Weibo Cai
- Department of Pharmaceutical SciencesUniversity of Wisconsin‐MadisonMadisonWI53705USA
- Departments of Radiology and Medical PhysicsUniversity of Wisconsin‐MadisonMadisonWI53705USA
| |
Collapse
|
14
|
Ferreira CA, Ehlerding EB, Rosenkrans ZT, Jiang D, Sun T, Aluicio-Sarduy E, Engle JW, Ni D, Cai W. 86/90Y-Labeled Monoclonal Antibody Targeting Tissue Factor for Pancreatic Cancer Theranostics. Mol Pharm 2020; 17:1697-1705. [PMID: 32202792 DOI: 10.1021/acs.molpharmaceut.0c00127] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Pancreatic cancer is highly aggressive, with a median survival time of less than 6 months and a 5-year overall survival rate of around 7%. The poor prognosis of PaCa is largely due to its advanced stage at diagnosis and the lack of efficient therapeutic options. Thus, the development of an efficient, multifunctional PaCa theranostic system is urgently needed. Overexpression of tissue factor (TF) has been associated with increased tumor growth, angiogenesis, and metastasis in many malignancies, including pancreatic cancer. Herein, we propose the use of a TF-targeted monoclonal antibody (ALT836) conjugated with the pair 86/90Y as a theranostic agent against pancreatic cancer. For methods, serial PET imaging with 86Y-DTPA-ALT836 was conducted to map the biodistribution the tracer in BXPC-3 tumor-bearing mice. 90Y-DTPA-ALT836 was employed as a therapeutic agent that also allowed tumor burden monitoring through Cherenkov luminescence imaging. The results were that the uptake of 86Y-DTPA-ALT836 in BXPC-3 xenograft tumors was high and increased over time up to 48 h postinjection (p.i.), corroborated through ex vivo biodistribution studies and further confirmed by Cherenkov luminescence Imaging. In therapeutic studies, 90Y-DTPA-ALT836 was found to slow tumor growth relative to the control groups and had significantly smaller (p < 0.05) tumor volumes 1 day p.i. Histological analysis of ex vivo tissues revealed significant damage to the treated tumors. The conclusion is that the use of the 86/90Y theranostic pair allows PET imaging with excellent tumor-to-background contrast and treatment of TF-expressing pancreatic tumors with promising therapeutic outcomes.
Collapse
Affiliation(s)
- Carolina A Ferreira
- Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Emily B Ehlerding
- Department of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Zachary T Rosenkrans
- Department of Pharmaceutical Sciences, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Dawei Jiang
- Department of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Tuanwei Sun
- Department of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Eduardo Aluicio-Sarduy
- Department of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Jonathan W Engle
- Department of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Dalong Ni
- Department of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Weibo Cai
- Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.,Department of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.,Department of Pharmaceutical Sciences, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| |
Collapse
|
15
|
Kostka L, Kotrchová L, Šubr V, Libánská A, Ferreira CA, Malátová I, Lee HJ, Barnhart TE, Engle JW, Cai W, Šírová M, Etrych T. HPMA-based star polymer biomaterials with tuneable structure and biodegradability tailored for advanced drug delivery to solid tumours. Biomaterials 2020; 235:119728. [DOI: 10.1016/j.biomaterials.2019.119728] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2019] [Revised: 11/27/2019] [Accepted: 12/22/2019] [Indexed: 02/03/2023]
|
16
|
Yu B, Ni D, Rosenkrans ZT, Barnhart TE, Wei H, Ferreira CA, Lan X, Engle JW, He Q, Yu F, Cai W. A "Missile-Detonation" Strategy to Precisely Supply and Efficiently Amplify Cerenkov Radiation Energy for Cancer Theranostics. Adv Mater 2019; 31:e1904894. [PMID: 31709622 PMCID: PMC6928399 DOI: 10.1002/adma.201904894] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/30/2019] [Revised: 10/24/2019] [Indexed: 05/02/2023]
Abstract
Cerenkov radiation (CR) from radionuclides can act as a built-in light source for cancer theranostics, opening a new horizon in biomedical applications. However, considerably low tumor-targeting efficiency of existing radionuclides and radionuclide-based nanomedicines limits the efficacy of CR-induced theranostics (CRIT). It remains a challenge to precisely and efficiently supply CR energy to the tumor site. Here, a "missile-detonation" strategy is reported, in which a high dose of p-SCN-Bn-deferoxamine-porphyrin-PEG nanocomplex (Df-PPN) is first adminstered as a CR energy receiver/missile to passively target to tumor, and then a low dose of the 89 Zr-labeled Df-PPN is administrated as a CR energy donor/detonator, which can be visualized and quantified by Cerenkov energy transfer imaging, positron-emission tomography, and fluorescence imaging. Based on homologous properties, the colocalization of Df-PPN and 89 Zr-Df-PPN in the tumor site is maximized and efficient CR energy transfer is enabled, which maximizes the tumor-targeted CRIT efficacy in an optimal spatiotemporal setting while also reducing adverse off-target effects from CRIT. This precise and efficient CRIT strategy causes significant tumor vascular damage and inhibited tumor growth.
Collapse
Affiliation(s)
- Bo Yu
- National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518060, China
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
- Key Laboratory for Green Chemical Process of Ministry of Education, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan, 430073, China
| | - Dalong Ni
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Zachary T Rosenkrans
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Todd E Barnhart
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Hao Wei
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430073, China
| | - Carolina A Ferreira
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Xiaoli Lan
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430073, China
| | - Jonathan W Engle
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Qianjun He
- National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518060, China
| | - Faquan Yu
- Key Laboratory for Green Chemical Process of Ministry of Education, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan, 430073, China
| | - Weibo Cai
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
| |
Collapse
|
17
|
Goel S, Ferreira CA, Dogra P, Yu B, Kutyreff CJ, Siamof CM, Engle JW, Barnhart TE, Cristini V, Wang Z, Cai W. Size-Optimized Ultrasmall Porous Silica Nanoparticles Depict Vasculature-Based Differential Targeting in Triple Negative Breast Cancer. Small 2019; 15:e1903747. [PMID: 31565854 PMCID: PMC6854296 DOI: 10.1002/smll.201903747] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/14/2019] [Revised: 09/14/2019] [Indexed: 05/26/2023]
Abstract
Rapid sequestration and prolonged retention of intravenously injected nanoparticles by the liver and spleen (reticuloendothelial system (RES)) presents a major barrier to effective delivery to the target site and hampers clinical translation of nanomedicine. Inspired by biological macromolecular drugs, synthesis of ultrasmall (diameter ≈12-15 nm) porous silica nanoparticles (UPSNs), capable of prolonged plasma half-life, attenuated RES sequestration, and accelerated hepatobiliary clearance, is reported. The study further investigates the effect of tumor vascularization on uptake and retention of UPSNs in two mouse models of triple negative breast cancer with distinctly different microenvironments. A semimechanistic mathematical model is developed to gain mechanistic insights into the interactions between the UPSNs and the biological entities of interest, specifically the RES. Despite similar systemic pharmacokinetic profiles, UPSNs demonstrate strikingly different tumor responses in the two models. Histopathology confirms the differences in vasculature and stromal status of the two models, and corresponding differences in the microscopic distribution of UPSNs within the tumors. The studies demonstrate the successful application of multidisciplinary and complementary approaches, based on laboratory experimentation and mathematical modeling, to concurrently design optimized nanomaterials, and investigate their complex biological interactions, in order to drive innovation and translation.
Collapse
Affiliation(s)
- Shreya Goel
- Materials Science Program, University of Wisconsin-Madison, Madison, Wisconsin, USA, 53705
| | - Carolina A. Ferreira
- Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wisconsin, USA, 53705
| | - Prashant Dogra
- Mathematics in Medicine Program, Houston Methodist Research Institute, Houston, Texas, USA, 77030
| | - Bo Yu
- Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin, USA, 53705
| | - Christopher J. Kutyreff
- Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA, 53705
| | - Cerise M. Siamof
- Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin, USA, 53705
| | - Jonathan W. Engle
- Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA, 53705
| | - Todd E. Barnhart
- Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA, 53705
| | - Vittorio Cristini
- Mathematics in Medicine Program, Houston Methodist Research Institute, Houston, Texas, USA, 77030
| | - Zhihui Wang
- Mathematics in Medicine Program, Houston Methodist Research Institute, Houston, Texas, USA, 77030
| | - Weibo Cai
- University of Wisconsin Carbone Cancer Centre, Madison, Wisconsin 53705
- Materials Science Program, University of Wisconsin-Madison, Madison, Wisconsin, USA, 53705
- Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wisconsin, USA, 53705
- Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin, USA, 53705
- Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA, 53705
| |
Collapse
|
18
|
Ni D, Wei H, Chen W, Bao Q, Rosenkrans ZT, Barnhart TE, Ferreira CA, Wang Y, Yao H, Sun T, Jiang D, Li S, Cao T, Liu Z, Engle JW, Hu P, Lan X, Cai W. Ceria Nanoparticles Meet Hepatic Ischemia-Reperfusion Injury: The Perfect Imperfection. Adv Mater 2019; 31:e1902956. [PMID: 31418951 PMCID: PMC6773480 DOI: 10.1002/adma.201902956] [Citation(s) in RCA: 121] [Impact Index Per Article: 24.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/08/2019] [Revised: 08/04/2019] [Indexed: 05/20/2023]
Abstract
The mononuclear phagocyte system (MPS, e.g., liver, spleen) is often treated as a "blackbox" by nanoresearchers in translating nanomedicines. Often, most of the injected nanomaterials are sequestered by the MPS, preventing their delivery to the desired disease areas. Here, this imperfection is exploited by applying nano-antioxidants with preferential liver uptake to directly prevent hepatic ischemia-reperfusion injury (IRI), which is a reactive oxygen species (ROS)-related disease. Ceria nanoparticles (NPs) are selected as a representative nano-antioxidant and the detailed mechanism of preventing IRI is investigated. It is found that ceria NPs effectively alleviate the clinical symptoms of hepatic IRI by scavenging ROS, inhibiting activation of Kupffer cells and monocyte/macrophage cells. The released pro-inflammatory cytokines are then significantly reduced and the recruitment and infiltration of neutrophils are minimized, which suppress subsequent inflammatory reaction involved in the liver. The protective effect of nano-antioxidants against hepatic IRI in living animals and the revealed mechanism herein suggests their future use for the treatment of hepatic IRI in the clinic.
Collapse
Affiliation(s)
- Dalong Ni
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Hao Wei
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430073, China
| | - Weiyu Chen
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Qunqun Bao
- State Key Laboratory of High Performance Ceramics and Superfine Microstructures, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai, 200050, China
| | - Zachary T Rosenkrans
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Todd E Barnhart
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Carolina A Ferreira
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Yanpu Wang
- Medical Isotopes Research Center and Department of Radiation Medicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China
| | - Heliang Yao
- State Key Laboratory of High Performance Ceramics and Superfine Microstructures, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai, 200050, China
| | - Tuanwei Sun
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Dawei Jiang
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Shiyong Li
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Tianye Cao
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Zhaofei Liu
- Medical Isotopes Research Center and Department of Radiation Medicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China
| | - Jonathan W Engle
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Ping Hu
- State Key Laboratory of High Performance Ceramics and Superfine Microstructures, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai, 200050, China
| | - Xiaoli Lan
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430073, China
| | - Weibo Cai
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
- University of Wisconsin Carbone Cancer Center, Madison, WI, 53705, USA
| |
Collapse
|
19
|
Abstract
Radio-nanomedicine, or the use of radiolabeled nanoparticles in nuclear medicine, has attracted much attention in the last few decades. Since the discovery of Cerenkov radiation and its employment in Cerenkov luminescence imaging, the combination of nanomaterials and Cerenkov radiation emitters has been revolutionizing the way nanomaterials are perceived in the field: from simple inert carriers of radioactivity to activatable nanomaterials for both diagnostic and therapeutic applications. Herein, we provide a comprehensive review on the types of nanomaterials that have been used to interact with Cerenkov radiation and the gamma and beta scintillation of radionuclides, as well as on their biological applications.
Collapse
Affiliation(s)
- Carolina A. Ferreira
- Departments of Radiology, Biomedical Engineering, and Medical Physics, University of Wisconsin – Madison, Madison, Wisconsin 53705, United States
| | - Dalong Ni
- Departments of Radiology, Biomedical Engineering, and Medical Physics, University of Wisconsin – Madison, Madison, Wisconsin 53705, United States
| | - Zachary T. Rosenkrans
- Departments of Radiology, Biomedical Engineering, and Medical Physics, University of Wisconsin – Madison, Madison, Wisconsin 53705, United States
| | - Weibo Cai
- Departments of Radiology, Biomedical Engineering, and Medical Physics, University of Wisconsin – Madison, Madison, Wisconsin 53705, United States
| |
Collapse
|
20
|
Affiliation(s)
- Carolina A. Ferreira
- Departments of Radiology, Biomedical Engineering, and Medical PhysicsUniversity of Wisconsin – Madison Madison Wisconsin 53705 USA
| | - Dalong Ni
- Departments of Radiology, Biomedical Engineering, and Medical PhysicsUniversity of Wisconsin – Madison Madison Wisconsin 53705 USA
| | - Zachary T. Rosenkrans
- Departments of Radiology, Biomedical Engineering, and Medical PhysicsUniversity of Wisconsin – Madison Madison Wisconsin 53705 USA
| | - Weibo Cai
- Departments of Radiology, Biomedical Engineering, and Medical PhysicsUniversity of Wisconsin – Madison Madison Wisconsin 53705 USA
| |
Collapse
|
21
|
Lee HJ, Ehlerding EB, Jiang D, Barnhart TE, Cao T, Wei W, Ferreira CA, Huang P, Engle JW, Cai W. Dual-labeled pertuzumab for multimodality image-guided ovarian tumor resection. Am J Cancer Res 2019; 9:1454-1468. [PMID: 31392081 PMCID: PMC6682714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2019] [Accepted: 06/14/2019] [Indexed: 06/10/2023] Open
Abstract
Pertuzumab is clinically employed in the treatment of cancers over-expressing human epidermal growth factor receptor 2 (HER2). Herein, we developed dual-labeled pertuzumab with a radionuclide (89Zr) and a near-infrared fluorophore (IRDye 800CW) to investigate the feasibility of utilizing dual-labeled monoclonal antibodies (mAbs) with numerous imaging modalities for preoperative imaging and image-guided surgery in ovarian cancer models. MAbs were dually-labeled with 89Zr and IRDye 800CW to generate 89Zr-Df-pertuzumab-800CW or 89Zr-Df-IgG-800CW. Serial positron emission tomography (PET) and near-infrared fluorescence (NIRF) images were acquired up to 72 hours after injection of dual-labeled mAbs to map the tracers' biodistributions. After the last time point, image-guided tumor resection was executed using different modalities (NIRF, Cerenkov luminescence [CL], and β particle imaging) and ex vivo studies including biodistribution assays and histology analysis were performed to confirm the in vivo imaging data. SKOV3 ovarian cancer cells showed high expression of HER2 and pertuzumab conjugated with Df and IRDye 800CW maintained its binding affinity for these cells. For PET imaging in subcutaneous xenograft ovarian cancer models, 89Zr-Df-pertuzumab-800CW showed a significantly higher tumor-to-muscle ratio compared to the nonspecific 89Zr-Df-IgG-800CW from 24 hours after injection through the last time point (72 h: 30.7 ± 7.4 vs. 7.5 ± 1.8, P < 0.01, n = 3-4). During image-guided surgery, three imaging modalities including NIRF, CL, and β particle imaging could detect ovarian cancer in both subcutaneous and orthotopic models and each exhibited its own imaging characteristics. In addition, ex vivo imaging and biodistribution studies as well as histology analysis corroborated the in vivo imaging results. Therefore, we concluded that this single radiolabeled tracer can provide all-in-one contrast for multiple imaging modalities. The dual-labeled mAbs may hold promise to be employed for image-guided tumor surgery as well as diagnosis and staging through balancing out the strengths and weaknesses of various modalities such as PET/CT, NIRF, CL, and β particle imaging.
Collapse
Affiliation(s)
- Hye Jin Lee
- Department of Pharmaceutical Sciences, University of Wisconsin-MadisonMadison, WI 53705, USA
| | - Emily B Ehlerding
- Department of Medical Physics, University of Wisconsin-MadisonMadison, WI 53705, USA
| | - Dawei Jiang
- Department of Radiology, University of Wisconsin-MadisonMadison, WI 53705, USA
- Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, Carson International Cancer Center, Laboratory of Evolutionary Theranostics, School of Biomedical Engineering, Health Science Center, Shenzhen UniversityShenzhen 518060, China
| | - Todd E Barnhart
- Department of Medical Physics, University of Wisconsin-MadisonMadison, WI 53705, USA
| | - Tianye Cao
- Department of Radiology, University of Wisconsin-MadisonMadison, WI 53705, USA
| | - Weijun Wei
- Department of Radiology, University of Wisconsin-MadisonMadison, WI 53705, USA
| | - Carolina A Ferreira
- Department of Biomedical Engineering, University of Wisconsin-MadisonMadison, WI 53706, USA
| | - Peng Huang
- Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, Carson International Cancer Center, Laboratory of Evolutionary Theranostics, School of Biomedical Engineering, Health Science Center, Shenzhen UniversityShenzhen 518060, China
| | - Jonathan W Engle
- Department of Medical Physics, University of Wisconsin-MadisonMadison, WI 53705, USA
| | - Weibo Cai
- Department of Pharmaceutical Sciences, University of Wisconsin-MadisonMadison, WI 53705, USA
- Department of Medical Physics, University of Wisconsin-MadisonMadison, WI 53705, USA
- Department of Radiology, University of Wisconsin-MadisonMadison, WI 53705, USA
- Department of Biomedical Engineering, University of Wisconsin-MadisonMadison, WI 53706, USA
- University of Wisconsin Carbone Cancer CenterMadison, WI 53705, USA
| |
Collapse
|
22
|
Ehlerding EB, Lee HJ, Jiang D, Ferreira CA, Zahm CD, Huang P, Engle JW, McNeel DG, Cai W. Antibody and fragment-based PET imaging of CTLA-4+ T-cells in humanized mouse models. Am J Cancer Res 2019; 9:53-63. [PMID: 30755811 PMCID: PMC6356917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2018] [Accepted: 12/13/2018] [Indexed: 06/09/2023] Open
Abstract
Imaging of immunotherapy targets using positron emission tomography (PET) can allow for noninvasive monitoring of their dynamic expression and may allow for patient stratification in the future. Therefore, two tracers targeting CTLA-4, one a full antibody and the other a F(ab')2 fragment, were radiolabeled with 64Cu and validated in humanized mouse models. Ipilimumab was digested to develop ipilimumab-F(ab')2, and both the intact antibody and the fragment were conjugated with NOTA to chelate 64Cu for PET. The tracers were administered to both control NBSGW mice and humanized mice (PBL mice, engrafted with human peripheral blood lymphocytes), and PET was conducted out to 48 h post-injection. PET region-of-interest analysis, ex vivo biodistribution studies, and tissue staining were used to confirm that the tracers specifically accumulated in CTLA-4+ tissues. Following injection of tracers (n = 3-5 per group), specific uptake was noted in the salivary gland tissues of the humanized mice. This uptake, a result of graft-versus-host disease onset, was proven to be due to human T-cells through staining of the tissues for human CD3 and CTLA-4. 64Cu-NOTA-ipilimumab demonstrated the highest absolute uptake in the salivary glands of PBL mice, peaking at 7.00 ± 2.19 %ID/g. In contrast, 64Cu-NOTA-ipilimumab-F(ab')2 uptake was 2.40 ± 0.86 %ID/g at the same time point. However, the F(ab')2 agent cleared from circulation more quickly than the intact antibody, providing higher salivary gland-to-blood ratios, which reached 1.78 ± 0.72 at 48 h post-injection, compared to 64Cu-NOTA-ipilimumab at 1.19 ± 0.49. Uptake of the tracers in the salivary glands of control mice, and the nonspecific tracer in the PBL mice, was lower at all time points as well. PET imaging with both 64Cu-NOTA-ipilimumab and 64Cu-NOTA-ipilimumab-F(ab')2 was able to localize CTLA-4+ tissues. These tracers may thus help elucidate the mechanisms of response to CTLA-4-targeted checkpoint immunotherapy treatments.
Collapse
Affiliation(s)
- Emily B Ehlerding
- Department of Medical Physics, University of Wisconsin-MadisonMadison, WI 53705, USA
| | - Hye Jin Lee
- Pharmaceutical Sciences Department, University of Wisconsin-MadisonMadison, WI 53705, USA
| | - Dawei Jiang
- Department of Radiology, University of Wisconsin-MadisonMadison, WI 53705, USA
- Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, Laboratory of Evolutionary Theranostics, School of Biomedical Engineering, Health Science Center, Shenzhen UniversityShenzhen 518060, China
| | - Carolina A Ferreira
- Department of Biomedical Engineering, University of Wisconsin-MadisonMadison, WI 53705, USA
| | - Christopher D Zahm
- Carbone Cancer Center, University of Wisconsin-MadisonMadison, WI 53705, USA
| | - Peng Huang
- Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, Laboratory of Evolutionary Theranostics, School of Biomedical Engineering, Health Science Center, Shenzhen UniversityShenzhen 518060, China
| | - Jonathan W Engle
- Department of Medical Physics, University of Wisconsin-MadisonMadison, WI 53705, USA
| | - Douglas G McNeel
- Carbone Cancer Center, University of Wisconsin-MadisonMadison, WI 53705, USA
- Department of Medicine, University of Wisconsin-MadisonMadison, WI 53705, USA
| | - Weibo Cai
- Department of Medical Physics, University of Wisconsin-MadisonMadison, WI 53705, USA
- Pharmaceutical Sciences Department, University of Wisconsin-MadisonMadison, WI 53705, USA
- Department of Radiology, University of Wisconsin-MadisonMadison, WI 53705, USA
- Department of Biomedical Engineering, University of Wisconsin-MadisonMadison, WI 53705, USA
- Carbone Cancer Center, University of Wisconsin-MadisonMadison, WI 53705, USA
| |
Collapse
|
23
|
Moukheiber D, Chitgupi U, Carter KA, Luo D, Sun B, Goel S, Ferreira CA, Engle JW, Wang D, Geng J, Zhang Y, Xia J, Cai W, Lovell JF. Surfactant-Stripped Pheophytin Micelles for Multimodal Tumor Imaging and Photodynamic Therapy. ACS Appl Bio Mater 2018; 2:544-554. [PMID: 31853516 DOI: 10.1021/acsabm.8b00703] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Porphyrin-based nanomaterials can inherently integrate multiple contrast imaging functionalities with phototherapeutic capabilities. We dispersed pheophytin (Pheo) into Pluronic F127 and carried out low-temperature surfactant-stripping to remove the bulk surfactant. Surfactant-stripped Pheo (ss-Pheo) micelles exhibited a similar size, but higher near-infrared fluorescence, compared to two other nanomaterials also with high porphyrin density (surfactant-stripped chlorophyll micelles and porphysomes). Singlet oxygen generation, which was higher for ss-Pheo, enabled photodynamic therapy (PDT). ss-Pheo provided contrast for photoacoustic and fluorescence imaging, and following seamless labeling with 64Cu, was used for positron emission tomography. ss-Pheo had a long blood circulation and favorable accumulation in an orthotopic murine mammary tumor model. Trimodal tumor imaging was demonstrated, and PDT resulted in delayed tumor growth.
Collapse
Affiliation(s)
- Dana Moukheiber
- Department of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York 14260, United States
| | - Upendra Chitgupi
- Department of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York 14260, United States
| | - Kevin A Carter
- Department of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York 14260, United States
| | - Dandan Luo
- Department of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York 14260, United States
| | - Boyang Sun
- Department of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York 14260, United States
| | - Shreya Goel
- Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Carolina A Ferreira
- Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Jonathan W Engle
- Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Depeng Wang
- Department of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York 14260, United States
| | - Jumin Geng
- Department of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York 14260, United States
| | - Yumiao Zhang
- Department of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York 14260, United States
| | - Jun Xia
- Department of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York 14260, United States
| | - Weibo Cai
- Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Jonathan F Lovell
- Department of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York 14260, United States
| |
Collapse
|
24
|
Yao G, Kang L, Li J, Long Y, Wei H, Ferreira CA, Jeffery JJ, Lin Y, Cai W, Wang X. Effective weight control via an implanted self-powered vagus nerve stimulation device. Nat Commun 2018; 9:5349. [PMID: 30559435 PMCID: PMC6297229 DOI: 10.1038/s41467-018-07764-z] [Citation(s) in RCA: 134] [Impact Index Per Article: 22.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Accepted: 11/26/2018] [Indexed: 12/13/2022] Open
Abstract
In vivo vagus nerve stimulation holds great promise in regulating food intake for obesity treatment. Here we present an implanted vagus nerve stimulation system that is battery-free and spontaneously responsive to stomach movement. The vagus nerve stimulation system comprises a flexible and biocompatible nanogenerator that is attached on the surface of stomach. It generates biphasic electric pulses in responsive to the peristalsis of stomach. The electric signals generated by this device can stimulate the vagal afferent fibers to reduce food intake and achieve weight control. This strategy is successfully demonstrated on rat models. Within 100 days, the average body weight is controlled at 350 g, 38% less than the control groups. This work correlates nerve stimulation with targeted organ functionality through a smart, self-responsive system, and demonstrated highly effective weight control. This work also provides a concept in therapeutic technology using artificial nerve signal generated from coordinated body activities. Developing new technologies for the neuromodulation of the vagus nerve can enable therapeutic strategies for body weight control in obese patients. Here, the authors present a battery-free self-powered implantable vagus nerve stimulation system that electrically responds to stomach movement.
Collapse
Affiliation(s)
- Guang Yao
- Department of Materials Science and Engineering, University of Wisconsin-Madison, Madison, WI, 53706, USA.,State Key Laboratory of Electronic Thin films and Integrated Devices, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610054, People's Republic of China
| | - Lei Kang
- Department of Radiology, University of Wisconsin-Madison, Madison, WI, 53705, USA.,Department of Nuclear Medicine, Peking University First Hospital, Beijing, 100034, People's Republic of China
| | - Jun Li
- Department of Materials Science and Engineering, University of Wisconsin-Madison, Madison, WI, 53706, USA
| | - Yin Long
- Department of Materials Science and Engineering, University of Wisconsin-Madison, Madison, WI, 53706, USA.,State Key Laboratory of Electronic Thin films and Integrated Devices, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610054, People's Republic of China
| | - Hao Wei
- Department of Radiology, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Carolina A Ferreira
- Department of Radiology, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Justin J Jeffery
- University of Wisconsin Carbone Cancer Center, Madison, WI, 53705, USA
| | - Yuan Lin
- State Key Laboratory of Electronic Thin films and Integrated Devices, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610054, People's Republic of China
| | - Weibo Cai
- Department of Radiology, University of Wisconsin-Madison, Madison, WI, 53705, USA.
| | - Xudong Wang
- Department of Materials Science and Engineering, University of Wisconsin-Madison, Madison, WI, 53706, USA.
| |
Collapse
|
25
|
Li J, Kang L, Long Y, Wei H, Yu Y, Wang Y, Ferreira CA, Yao G, Zhang Z, Carlos C, German L, Lan X, Cai W, Wang X. Implanted Battery-Free Direct-Current Micro-Power Supply from in Vivo Breath Energy Harvesting. ACS Appl Mater Interfaces 2018; 10:42030-42038. [PMID: 30444344 PMCID: PMC6456428 DOI: 10.1021/acsami.8b15619] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
In vivo biomechanical energy harvesting by implanted nanogenerators (i-NGs) is promising for self-powered implantable medical devices (IMDs). One critical challenge to reach practical applications is the requirement of continuous direct-current (dc) output, while the low-frequency body activities typically generate discrete electrical pulses. Here, we developed an ultrastretchable micrograting i-NG system that could function as a battery-free dc micro-power supply. Packaged by a soft silicone elastomer with a cavity design, the i-NG exhibited an ultralow Young's modulus of ∼45 kPa and a high biocompatibility to soft biological tissues. The i-NG was implanted inside the abdominal cavity of Sprague Dawley adult rats and directly converted the slow diaphragm movement during normal respiration into a high-frequency alternative current electrical output, which was readily transmitted into a continuous ∼2.2 V dc output after being integrated with a basic electrical circuit. A light-emitting diode was constantly operated by the breath-driven i-NG without the aid of any battery component. This solely biomechanical energy-driven dc micro-power supply offers a promising solution for the development of self-powered IMDs.
Collapse
Affiliation(s)
- Jun Li
- Department of Materials Science and Engineering , University of Wisconsin-Madison , Madison , Wisconsin 53706 , United States
| | - Lei Kang
- Department of Radiology and Medical Physics , University of Wisconsin-Madison , Madison , Wisconsin 53705 , United States
- Department of Nuclear Medicine , Peking University First Hospital , Beijing 100034 , China
| | - Yin Long
- Department of Materials Science and Engineering , University of Wisconsin-Madison , Madison , Wisconsin 53706 , United States
- State Key Laboratory of Electronic Thin Films and Integrated Devices, School of Optoelectronic Information , University of Electronic Science and Technology of China (UESTC) , Chengdu 610054 , China
| | - Hao Wei
- Department of Radiology and Medical Physics , University of Wisconsin-Madison , Madison , Wisconsin 53705 , United States
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College , Huazhong University of Science and Technology , Wuhan 430022 , China
| | - Yanhao Yu
- Department of Materials Science and Engineering , University of Wisconsin-Madison , Madison , Wisconsin 53706 , United States
| | - Yizhan Wang
- Department of Materials Science and Engineering , University of Wisconsin-Madison , Madison , Wisconsin 53706 , United States
| | - Carolina A Ferreira
- Department of Radiology and Medical Physics , University of Wisconsin-Madison , Madison , Wisconsin 53705 , United States
| | - Guang Yao
- Department of Materials Science and Engineering , University of Wisconsin-Madison , Madison , Wisconsin 53706 , United States
- State Key Laboratory of Electronic Thin Films and Integrated Devices, School of Optoelectronic Information , University of Electronic Science and Technology of China (UESTC) , Chengdu 610054 , China
| | - Ziyi Zhang
- Department of Materials Science and Engineering , University of Wisconsin-Madison , Madison , Wisconsin 53706 , United States
| | - Corey Carlos
- Department of Materials Science and Engineering , University of Wisconsin-Madison , Madison , Wisconsin 53706 , United States
| | - Lazarus German
- Department of Materials Science and Engineering , University of Wisconsin-Madison , Madison , Wisconsin 53706 , United States
| | - Xiaoli Lan
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College , Huazhong University of Science and Technology , Wuhan 430022 , China
| | - Weibo Cai
- Department of Materials Science and Engineering , University of Wisconsin-Madison , Madison , Wisconsin 53706 , United States
- Department of Radiology and Medical Physics , University of Wisconsin-Madison , Madison , Wisconsin 53705 , United States
| | - Xudong Wang
- Department of Materials Science and Engineering , University of Wisconsin-Madison , Madison , Wisconsin 53706 , United States
| |
Collapse
|
26
|
Ni D, Ferreira CA, Barnhart TE, Quach V, Yu B, Jiang D, Wei W, Liu H, Engle JW, Hu P, Cai W. Magnetic Targeting of Nanotheranostics Enhances Cerenkov Radiation-Induced Photodynamic Therapy. J Am Chem Soc 2018; 140:14971-14979. [PMID: 30336003 DOI: 10.1021/jacs.8b09374] [Citation(s) in RCA: 117] [Impact Index Per Article: 19.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The interaction between radionuclides and nanomaterials could generate Cerenkov radiation (CR) for CR-induced photodynamic therapy (PDT) without requirement of external light excitation. However, the relatively weak CR interaction leaves clinicians uncertain about the benefits of this new type of PDT. Therefore, a novel strategy to amplify the therapeutic effect of CR-induced PDT is imminently required to overcome the disadvantages of traditional nanoparticulate PDT such as tissue penetration limitation, external light dependence, and low tumor accumulation of photosensitizers. Herein, magnetic nanoparticles (MNPs) with 89Zr radiolabeling and porphyrin molecules (TCPP) surface modification (i.e., 89Zr-MNP/TCPP) were synthesized for CR-induced PDT with magnetic targeting tumor delivery. As a novel strategy to break the depth and light dependence of traditional PDT, these 89Zr-MNP/TCPP exhibited high tumor accumulation under the presence of an external magnetic field, contributing to excellent tumor photodynamic therapeutic effect together with fluorescence, Cerenkov luminescence (CL), and Cerenkov resonance energy transfer (CRET) multimodal imaging to monitor the therapeutic process. The present study provides a major step forward in photodynamic therapy by developing an advanced phototherapy tool of magnetism-enhanced CR-induced PDT for effective targeting and treatment of tumors.
Collapse
Affiliation(s)
- Dalong Ni
- Departments of Radiology and Medical Physics , University of Wisconsin-Madison , Wisconsin 53705 , United States
| | - Carolina A Ferreira
- Departments of Radiology and Medical Physics , University of Wisconsin-Madison , Wisconsin 53705 , United States
| | - Todd E Barnhart
- Departments of Radiology and Medical Physics , University of Wisconsin-Madison , Wisconsin 53705 , United States
| | - Virginia Quach
- Departments of Radiology and Medical Physics , University of Wisconsin-Madison , Wisconsin 53705 , United States
| | - Bo Yu
- Departments of Radiology and Medical Physics , University of Wisconsin-Madison , Wisconsin 53705 , United States
| | - Dawei Jiang
- Departments of Radiology and Medical Physics , University of Wisconsin-Madison , Wisconsin 53705 , United States
| | - Weijun Wei
- Departments of Radiology and Medical Physics , University of Wisconsin-Madison , Wisconsin 53705 , United States
| | - Huisheng Liu
- Interdisciplinary Innovation Institute of Medicine & Engineering, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Biological Science and Medical Engineering , Beihang University , Beijing 100191 , China
| | - Jonathan W Engle
- Departments of Radiology and Medical Physics , University of Wisconsin-Madison , Wisconsin 53705 , United States
| | - Ping Hu
- State Key Laboratory of High Performance Ceramics and Superfine Microstructures, Shanghai Institute of Ceramics , Chinese Academy of Sciences , Shanghai 200050 , China
| | - Weibo Cai
- Departments of Radiology and Medical Physics , University of Wisconsin-Madison , Wisconsin 53705 , United States.,University of Wisconsin Carbone Cancer Center , Madison , Wisconsin 53705 , United States
| |
Collapse
|
27
|
Abstract
Reactive oxygen and nitrogen species (RONS) are essential for normal physiological processes and play important roles in cell signaling, immunity, and tissue homeostasis. However, excess radical species are implicated in the development and augmented pathogenesis of various diseases. Several antioxidants may restore the chemical balance, but their use is limited by disappointing results of clinical trials. Nanoparticles are an attractive therapeutic alternative because they can change the biodistribution profile of antioxidants, and possess intrinsic ability to scavenge RONS. Herein, we review the types of RONS, how they are implicated in several diseases, and the types of nanoparticles with inherent antioxidant capability, their mechanisms of action, and their biological applications.
Collapse
Affiliation(s)
| | - Dalong Ni
- Address correspondence to Dalong Ni, ; Weibo Cai,
| | | | - Weibo Cai
- Address correspondence to Dalong Ni, ; Weibo Cai,
| |
Collapse
|
28
|
Ferreira CA, Baptista R, Oliveira-Santos M, Milner J, Marinho V, Ferreira J, Dias P, Moura J, Pego M. 3140The SCORE and the ASCVD risk prediction scores in a Southern Europe population: very good at identifying very low risk patients. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.3140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- C A Ferreira
- University Hospitals of Coimbra, Cardiology A, Coimbra, Portugal
| | - R Baptista
- University Hospitals of Coimbra, Cardiology A, Coimbra, Portugal
| | | | - J Milner
- University Hospitals of Coimbra, Cardiology A, Coimbra, Portugal
| | - V Marinho
- University Hospitals of Coimbra, Cardiology A, Coimbra, Portugal
| | - J Ferreira
- University Hospitals of Coimbra, Cardiology A, Coimbra, Portugal
| | - P Dias
- University Hospitals of Coimbra, Internal Medicine A, Coimbra, Portugal
| | - J Moura
- University Hospitals of Coimbra, Internal Medicine A, Coimbra, Portugal
| | - M Pego
- University Hospitals of Coimbra, Cardiology A, Coimbra, Portugal
| |
Collapse
|
29
|
Ehlerding EB, Ferreira CA, Aluicio-Sarduy E, Jiang D, Lee HJ, Theuer CP, Engle JW, Cai W. 86/90Y-Based Theranostics Targeting Angiogenesis in a Murine Breast Cancer Model. Mol Pharm 2018; 15:2606-2613. [PMID: 29787283 PMCID: PMC6028311 DOI: 10.1021/acs.molpharmaceut.8b00133] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Angiogenesis is widely recognized as one of the hallmarks of cancer. Therefore, imaging and therapeutic agents targeted to angiogenic vessels may be widely applicable in many types of cancer. To this end, the theranostic isotope pair, 86Y and 90Y, were used to create a pair of agents for targeted imaging and therapy of neovasculature in murine breast cancer models using a chimeric anti-CD105 antibody, TRC105. Serial positron emission tomography imaging with 86Y-DTPA-TRC105 demonstrated high uptake in 4T1 tumors, peaking at 9.6 ± 0.3%ID/g, verified through ex vivo studies. Additionally, promising results were obtained in therapeutic studies with 90Y-DTPA-TRC105, wherein significantly ( p < 0.05) decreased tumor volumes were observed for the targeted treatment group over all control groups near the end of the study. Dosimetric extrapolation and tissue histological analysis corroborated trends found in vivo. Overall, this study demonstrated the potential of the pair 86/90Y for theranostics, enabling personalized treatments for cancer.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/chemistry
- Antibodies, Monoclonal/pharmacology
- Antibodies, Monoclonal/therapeutic use
- Antineoplastic Agents/chemistry
- Antineoplastic Agents/pharmacology
- Antineoplastic Agents/therapeutic use
- Cell Line, Tumor/transplantation
- Drug Screening Assays, Antitumor
- Female
- Humans
- Immunoconjugates/chemistry
- Immunoconjugates/pharmacology
- Immunoconjugates/therapeutic use
- Mammary Neoplasms, Experimental/diagnostic imaging
- Mammary Neoplasms, Experimental/pathology
- Mammary Neoplasms, Experimental/radiotherapy
- Mice
- Mice, Inbred BALB C
- Neovascularization, Pathologic/diagnostic imaging
- Neovascularization, Pathologic/drug therapy
- Positron-Emission Tomography/methods
- Radioimmunotherapy/methods
- Theranostic Nanomedicine/methods
- Tissue Distribution
- Treatment Outcome
- Yttrium Radioisotopes/chemistry
- Yttrium Radioisotopes/pharmacology
- Yttrium Radioisotopes/therapeutic use
Collapse
Affiliation(s)
| | - Carolina A Ferreira
- Department of Biomedical Engineering , Univesity of Wisconsin-Madison , Madison , Wisconsin 53706 , United States
| | | | | | | | - Charles P Theuer
- TRACON Pharmaceuticals, Inc. , San Diego , California 92122 , United States
| | | | - Weibo Cai
- Department of Biomedical Engineering , Univesity of Wisconsin-Madison , Madison , Wisconsin 53706 , United States
- Carbone Comprehensive Cancer Center , University of Wisconsin-Madison , Madison , Wisconsin 53792 , United States
| |
Collapse
|
30
|
Abstract
Peripheral arterial disease (PAD) consists of a persistent obstruction of lower-extremity arteries further from the aortic bifurcation attributable to atherosclerosis. PAD is correlated with an elevated risk of morbidity and mortality as well as of deterioration of the quality of life with claudication and chronic leg ischemia being the most frequent complications. Therapeutic angiogenesis is a promising therapeutic strategy that aims to restore the blood flow to the ischemic limb. In this context, assessing the efficacy of pro-angiogenic treatment using a reliable noninvasive imaging technique would greatly benefit the implementation of this therapeutic approach. Herein, we describe the angiogenesis and perfusion recovery characteristics of a mouse model of PAD via in vivo positron emission tomography (PET) imaging of CD146 expression. For that, ischemia was generated by ligation and excision of the right femoral artery of Balb/C mice and confirmed through laser Doppler imaging. The angiogenic process, induced by ischemia, was noninvasively monitored and quantified through PET imaging of CD146 expression in the injured leg using a 64Cu-labeled anti-CD146 monoclonal antibody, 64Cu-NOTA-YY146, at post-operative days 3, 10, and 17. The CD146-specific character of 64Cu-NOTA-YY146 was verified via a blocking study performed in another cohort at day 10 after surgery. Tracer uptake was correlated with in situ CD146 expression by histological analysis. PET scan results indicated that 64Cu-NOTA-YY146 uptake in the injured leg was significantly higher, with the highest uptake with a value of 14.1 ± 2.0 %ID/g at post-operative day 3, compared to the normal contralateral hindlimb, at all time points (maximum uptake of 2.2 ± 0.2 %ID/g). The pre-injection of a blocking dose resulted in a significantly lower tracer uptake in the ischemic hindlimb on day 10 after surgery, confirming tracer specificity. CD146/CD31 immunofluorescent co-staining showed an excellent correlation between the high uptake of the tracer with in situ CD146 expression levels and a marked co-localization of CD146 and CD31 signals. In conclusion, persistent and CD146-specific tracer accumulation in the ischemic hindlimb was observed, confirming the feasibility of 64Cu-NOTA-YY146 to be used as an imaging agent to monitor the progression of angiogenesis and recovery in future PAD research.
Collapse
Affiliation(s)
- Carolina A Ferreira
- Department of Biomedical Engineering , University of Wisconsin-Madison , Madison , Wisconsin , 53706 , United States
| | - Reinier Hernandez
- Department of Radiology , University of Wisconsin-Madison , Madison , Wisconsin , 53792 , United States
| | - Yunan Yang
- Department of Radiology , University of Wisconsin-Madison , Madison , Wisconsin , 53792 , United States
| | - Hector F Valdovinos
- Department of Medical Physics , University of Wisconsin-Madison , Madison , Wisconsin , 53705 , United States
| | - Jonathan W Engle
- Department of Medical Physics , University of Wisconsin-Madison , Madison , Wisconsin , 53705 , United States
| | - Weibo Cai
- Department of Biomedical Engineering , University of Wisconsin-Madison , Madison , Wisconsin , 53706 , United States.,Department of Radiology , University of Wisconsin-Madison , Madison , Wisconsin , 53792 , United States.,Department of Medical Physics , University of Wisconsin-Madison , Madison , Wisconsin , 53705 , United States.,University of Wisconsin Carbone Cancer Center , Madison , Wisconsin , 53792 , United States
| |
Collapse
|
31
|
Goel S, Ferreira CA, Chen F, Ellison PA, Siamof CM, Barnhart TE, Cai W. Activatable Hybrid Nanotheranostics for Tetramodal Imaging and Synergistic Photothermal/Photodynamic Therapy. Adv Mater 2018; 30:10.1002/adma.201704367. [PMID: 29266476 PMCID: PMC5805572 DOI: 10.1002/adma.201704367] [Citation(s) in RCA: 132] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/02/2017] [Revised: 10/03/2017] [Indexed: 05/20/2023]
Abstract
A multifunctional core-satellite nanoconstruct is designed by assembling copper sulfide (CuS) nanoparticles on the surface of [89 Zr]-labeled hollow mesoporous silica nanoshells filled with porphyrin molecules, for effective cancer imaging and therapy. The hybrid nanotheranostic demonstrates three significant features: (1) simple and robust construction from biocompatible building blocks, demonstrating prolonged blood retention, enhanced tumor accumulation, and minimal long-term systemic toxicity, (2) rationally selected functional moieties that interact together to enable simultaneous tetramodal (positron emission tomography/fluorescence/Cerenkov luminescence/Cerenkov radiation energy transfer) imaging for rapid and accurate delineation of tumors and multimodal image-guided therapy in vivo, and (3) synergistic interaction between CuS-mediated photothermal therapy and porphyrin-mediated photodynamic therapy which results in complete tumor elimination within a day of treatment with no visible recurrence or side effects. Overall, this proof-of-concept study illustrates an efficient, generalized approach to design high-performance core-satellite nanohybrids that can be easily tailored to combine a wide variety of imaging and therapeutic modalities for improved and personalized cancer theranostics in the future.
Collapse
Affiliation(s)
- Shreya Goel
- Department of Materials Science and Engineering, University of Wisconsin - Madison, WI, 53705, USA
| | - Carolina A Ferreira
- Department of Biomedical Engineering, University of Wisconsin - Madison, WI, 53705, USA
| | - Feng Chen
- Department of Radiology, University of Wisconsin - Madison, WI, 53705, USA
| | - Paul A Ellison
- Department of Medical Physics, University of Wisconsin - Madison, WI, 53705, USA
| | - Cerise M Siamof
- Department of Radiology, University of Wisconsin - Madison, WI, 53705, USA
| | - Todd E Barnhart
- Department of Medical Physics, University of Wisconsin - Madison, WI, 53705, USA
| | - Weibo Cai
- Department of Materials Science and Engineering, University of Wisconsin - Madison, WI, 53705, USA
- Department of Biomedical Engineering, University of Wisconsin - Madison, WI, 53705, USA
- Department of Radiology, University of Wisconsin - Madison, WI, 53705, USA
- Department of Medical Physics, University of Wisconsin - Madison, WI, 53705, USA
- University of Wisconsin Carbone Cancer Center, Madison, WI, 53705, USA
| |
Collapse
|
32
|
Yu B, Wei H, He Q, Ferreira CA, Kutyreff CJ, Ni D, Rosenkrans ZT, Cheng L, Yu F, Engle JW, Lan X, Cai W. Efficient Uptake of 177 Lu-Porphyrin-PEG Nanocomplexes by Tumor Mitochondria for Multimodal-Imaging-Guided Combination Therapy. Angew Chem Int Ed Engl 2018; 57:218-222. [PMID: 29092090 PMCID: PMC5745268 DOI: 10.1002/anie.201710232] [Citation(s) in RCA: 69] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2017] [Indexed: 11/09/2022]
Abstract
The benefits to intracellular drug delivery from nanomedicine have been limited by biological barriers and to some extent by targeting capability. We investigated a size-controlled, dual tumor-mitochondria-targeted theranostic nanoplatform (Porphyrin-PEG Nanocomplexes, PPNs). The maximum tumor accumulation (15.6 %ID g-1 , 72 h p.i.) and ideal tumor-to-muscle ratio (16.6, 72 h p.i.) was achieved using an optimized PPN particle size of approximately 10 nm, as measured by using PET imaging tracing. The stable coordination of PPNs with 177 Lu enables the integration of fluorescence imaging (FL) and photodynamic therapy (PDT) with positron emission tomography (PET) imaging and internal radiotherapy (RT). Furthermore, the efficient tumor and mitochondrial uptake of 177 Lu-PPNs greatly enhanced the efficacies of RT and/or PDT. This work developed a facile approach for the fabrication of tumor-targeted multi-modal nanotheranostic agents, which enables precision and radionuclide-based combination tumor therapy.
Collapse
Affiliation(s)
- Bo Yu
- National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518060, China
- Departments of Radiology and Medical Physics, University of Wisconsin, Madison, WI, 53705, USA
- Key Laboratory for Green Chemical Process of Ministry of Education, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan, 430205, China
| | - Hao Wei
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430073, China
| | - Qianjun He
- National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518060, China
| | - Carolina A Ferreira
- Departments of Radiology and Medical Physics, University of Wisconsin, Madison, WI, 53705, USA
| | - Christopher J Kutyreff
- Departments of Radiology and Medical Physics, University of Wisconsin, Madison, WI, 53705, USA
| | - Dalong Ni
- Departments of Radiology and Medical Physics, University of Wisconsin, Madison, WI, 53705, USA
| | | | - Liang Cheng
- Institute of Functional Nano & Soft Materials (FUNSOM), Collaborative Innovation Center of Suzhou Nano Science and Technology, Soochow University, Suzhou, 215123, China
| | - Faquan Yu
- Key Laboratory for Green Chemical Process of Ministry of Education, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan, 430205, China
| | - Jonathan W Engle
- Departments of Radiology and Medical Physics, University of Wisconsin, Madison, WI, 53705, USA
| | - Xiaoli Lan
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430073, China
| | - Weibo Cai
- Departments of Radiology and Medical Physics, University of Wisconsin, Madison, WI, 53705, USA
- School of Pharmacy, University of Wisconsin, Madison, WI, 53705, USA
- University of Wisconsin Carbone Cancer Center, Madison, WI, 53705, USA
| |
Collapse
|
33
|
Yu B, Wei H, He Q, Ferreira CA, Kutyreff CJ, Ni D, Rosenkrans ZT, Cheng L, Yu F, Engle JW, Lan X, Cai W. Efficient Uptake of 177
Lu-Porphyrin-PEG Nanocomplexes by Tumor Mitochondria for Multimodal-Imaging-Guided Combination Therapy. Angew Chem Int Ed Engl 2017. [DOI: 10.1002/ange.201710232] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Bo Yu
- National-Regional Key Technology Engineering Laboratory for Medical Ultrasound; Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging; School of Biomedical Engineering, Health Science Center; Shenzhen University; Shenzhen 518060 China
- Departments of Radiology and Medical Physics; University of Wisconsin; Madison WI 53705 USA
- Key Laboratory for Green Chemical Process of Ministry of Education; School of Chemical Engineering and Pharmacy; Wuhan Institute of Technology; Wuhan 430205 China
| | - Hao Wei
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College; Huazhong University of Science and Technology; Wuhan 430073 China
| | - Qianjun He
- National-Regional Key Technology Engineering Laboratory for Medical Ultrasound; Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging; School of Biomedical Engineering, Health Science Center; Shenzhen University; Shenzhen 518060 China
| | - Carolina A. Ferreira
- Departments of Radiology and Medical Physics; University of Wisconsin; Madison WI 53705 USA
| | | | - Dalong Ni
- Departments of Radiology and Medical Physics; University of Wisconsin; Madison WI 53705 USA
| | | | - Liang Cheng
- Institute of Functional Nano & Soft Materials (FUNSOM); Collaborative Innovation Center of Suzhou Nano Science and Technology; Soochow University; Suzhou 215123 China
| | - Faquan Yu
- Key Laboratory for Green Chemical Process of Ministry of Education; School of Chemical Engineering and Pharmacy; Wuhan Institute of Technology; Wuhan 430205 China
| | - Jonathan W. Engle
- Departments of Radiology and Medical Physics; University of Wisconsin; Madison WI 53705 USA
| | - Xiaoli Lan
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College; Huazhong University of Science and Technology; Wuhan 430073 China
| | - Weibo Cai
- Departments of Radiology and Medical Physics; University of Wisconsin; Madison WI 53705 USA
- School of Pharmacy; University of Wisconsin; Madison WI 53705 USA
- University of Wisconsin Carbone Cancer Center; Madison WI 53705 USA
| |
Collapse
|
34
|
Ehlerding EB, Lacognata S, Jiang D, Ferreira CA, Goel S, Hernandez R, Jeffery JJ, Theuer CP, Cai W. Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody. Eur J Nucl Med Mol Imaging 2017; 45:123-131. [PMID: 28821931 DOI: 10.1007/s00259-017-3793-2] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2017] [Accepted: 07/25/2017] [Indexed: 12/26/2022]
Abstract
PURPOSE Increased angiogenesis is a marker of aggressiveness in many cancers. Targeted radionuclide therapy of these cancers with angiogenesis-targeting agents may curtail this increased blood vessel formation and slow the growth of tumors, both primary and metastatic. CD105, or endoglin, has a primary role in angiogenesis in a number of cancers, making this a widely applicable target for targeted radioimmunotherapy. METHODS The anti-CD105 antibody, TRC105 (TRACON Pharmaceuticals), was conjugated with DTPA for radiolabeling with 177Lu (t 1/2 6.65 days). Balb/c mice were implanted with 4T1 mammary carcinoma cells, and five study groups were used: 177Lu only, TRC105 only, 177Lu-DTPA-IgG (a nonspecific antibody), 177Lu-DTPA-TRC105 low-dose, and 177Lu-DTPA-TRC105 high-dose. Toxicity of the agent was monitored by body weight measurements and analysis of blood markers. Biodistribution studies of 177Lu-DTPA-TRC105 were also performed at 1 and 7 days after injection. Ex vivo histology studies of various tissues were conducted at 1, 7, and 30 days after injection of high-dose 177Lu-DTPA-TRC105. RESULTS Biodistribution studies indicated steady uptake of 177Lu-DTPA-TRC105 in 4T1 tumors between 1 and 7 days after injection (14.3 ± 2.3%ID/g and 11.6 ± 6.1%ID/g, respectively; n = 3) and gradual clearance from other organs. Significant inhibition of tumor growth was observed in the high-dose group, with a corresponding significant increase in survival (p < 0.001, all groups). In most study groups (all except the nonspecific IgG group), the body weights of the mice did not decrease by more than 10%, indicating the safety of the injected agents. Serum alanine transaminase levels remained nearly constant indicating no damage to the liver (a primary clearance organ of the agent), and this was confirmed by ex vivo histological analyses. CONCLUSION 177Lu-DTPA-TRC105, when administered at a sufficient dose, is able to curtail tumor growth and provide a significant survival benefit without off-target toxicity. Thus, this targeted agent could be used in combination with other treatment options to slow tumor growth allowing the other agents to be more effective.
Collapse
Affiliation(s)
- Emily B Ehlerding
- Department of Medical Physics, University of Wisconsin - Madison, 1111 Highland Avenue, Madison, WI, 53705, USA
| | - Saige Lacognata
- Department of Radiology, University of Wisconsin - Madison, Madison, WI, USA
| | - Dawei Jiang
- Department of Radiology, University of Wisconsin - Madison, Madison, WI, USA
| | - Carolina A Ferreira
- Department of Biomedical Engineering, University of Wisconsin - Madison, Madison, WI, USA
| | - Shreya Goel
- Department of Materials Science and Engineering, University of Wisconsin - Madison, Madison, WI, USA
| | - Reinier Hernandez
- Department of Medical Physics, University of Wisconsin - Madison, 1111 Highland Avenue, Madison, WI, 53705, USA
| | - Justin J Jeffery
- Small Animal Imaging Facility, University of Wisconsin - Madison, Madison, WI, USA
| | | | - Weibo Cai
- Department of Medical Physics, University of Wisconsin - Madison, 1111 Highland Avenue, Madison, WI, 53705, USA. .,Department of Radiology, University of Wisconsin - Madison, Madison, WI, USA. .,Department of Biomedical Engineering, University of Wisconsin - Madison, Madison, WI, USA. .,Department of Materials Science and Engineering, University of Wisconsin - Madison, Madison, WI, USA.
| |
Collapse
|
35
|
Ai F, Ferreira CA, Chen F, Cai W. Engineering of radiolabeled iron oxide nanoparticles for dual-modality imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2015; 8:619-30. [PMID: 26692551 DOI: 10.1002/wnan.1386] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/28/2015] [Revised: 11/14/2015] [Accepted: 11/19/2015] [Indexed: 12/27/2022]
Abstract
Over the last decade, radiolabeled iron oxide nanoparticles have been developed as promising contrast agents for dual-modality positron emission tomography/magnetic resonance imaging (PET/MRI) or single-photon emission computed tomography/magnetic resonance imaging (SPECT/MRI). The combination of PET (or SPECT) with MRI can offer synergistic advantages for noninvasive, sensitive, high-resolution, and quantitative imaging, which is suitable for early detection of various diseases such as cancer. Here, we summarize the recent advances on radiolabeled iron oxide nanoparticles for dual-modality imaging, through the use of a variety of PET (and SPECT) isotopes by using both chelator-based and chelator-free radiolabeling techniques. WIREs Nanomed Nanobiotechnol 2016, 8:619-630. doi: 10.1002/wnan.1386.
Collapse
Affiliation(s)
- Fanrong Ai
- School of Mechanical & Electrical Engineering, Nanchang University, Jiangxi, China.,Department of Radiology, University of Wisconsin - Madison, Madison, WI, USA
| | - Carolina A Ferreira
- Department of Biomedical Engineering, University of Wisconsin - Madison, Madison, WI, USA
| | - Feng Chen
- Department of Radiology, University of Wisconsin - Madison, Madison, WI, USA
| | - Weibo Cai
- Department of Radiology, University of Wisconsin - Madison, Madison, WI, USA.,Department of Biomedical Engineering, University of Wisconsin - Madison, Madison, WI, USA.,Department of Medical Physics, University of Wisconsin - Madison, Madison, WI, USA.,Carbone Cancer Center, University of Wisconsin, Madison, WI, USA
| |
Collapse
|
36
|
Sette JBC, Santana MRO, Martins TPG, Alves SG, Keiralla LCB, Alexandre LM, Ferreira CA, Lopes RW, Penhalves FB, Smanio PEP. IA 002 Ankle Brachial Index (ABI) and its Associations with Myocardial Scintillography (MS) and Cineangiocoronariography in Elderly Patients: A 2-year Follow up. ATHEROSCLEROSIS SUPP 2009. [DOI: 10.1016/s1567-5688(09)71740-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
37
|
Salgado KCPC, Von Pinho EVR, Guimarães CT, Von Pinho RG, Ferreira CA, Andrade V. Mapping of quantitative trait locus associated with maize tolerance to high seed drying temperature. Genet Mol Res 2008; 7:1319-26. [PMID: 19065767 DOI: 10.4238/vol7-4gmr504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
quantitative trait locus (QTL) mapping and identification of traits of agronomic importance is important in the process of molecular marker-assisted selection in breeding programs. The molecular map of maize is well saturated and QTL and simple sequence repeat (SSR) markers have been identified, whereas few markers linked to seed quality traits are included. The present study aimed to identify QTL and the gene action and to quantify the effects of these regions in the phenotypic variation related to maize tolerance to high seed drying temperature. SSR markers and 129 segregating families of F2 plants of the cross of intolerant and tolerant lines were used in regression and composite interval mapping methods. Three maize QTL associated with tolerance to high seed drying temperature were identified and mapped to chromosomes 6 and 8, explaining 39% of the phenotypic variation of the trait with additive, dominance and overdominance gene action. These markers seem to be effectively associated with the evaluated trait, since all were mapped near genes whose expression products were associated with seed desiccation tolerance.
Collapse
Affiliation(s)
- K C P C Salgado
- Laboratório de Sementes, Departamento de Agricultura, Universidade Federal de Lavras, Lavras, MG, Brasil
| | | | | | | | | | | |
Collapse
|
38
|
Ferreira CA. Autoimmune diseases: beyond clinical and/or immune parameters to pathogenic process. Pathol Biol (Paris) 2006; 54:119-21. [PMID: 16495021 DOI: 10.1016/j.patbio.2005.08.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Concepts of autoimmune diseases (AD) over the last number of years are critically considered according to the contribution or lack thereof they have made to the understanding of these diseases. Specifically, terms have come down to contemporary researchers that have generally been left unquestioned, and therefore inadequate to accurately describe or clearly define clinical phenomena. An approach to AD that embraces research results from recent studies holds significant potential.
Collapse
|
39
|
Passos DT, Ferreira CA, da Silva SS, Richter MF, Ozaki LS. Detection of genomic variability in different populations of the cattle tick Boophilus microplus in southern Brazil. Vet Parasitol 1999; 87:83-92. [PMID: 10628703 DOI: 10.1016/s0304-4017(99)00147-8] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
DNA from seven isolates of the cattle tick Boophilus microplus was analyzed by restriction fragment length polymorphism (RFLP). Three different cDNA clones, named P-9, P-25 and CP-12, isolated from a B. microplus cDNA library, were used as DNA probes. DNA sequences of P-9 have high similarity to ribosomal genes, whereas P-25 does not show significant homology with known sequences within databases. CP-12 is a cDNA clone encoding a cysteine endopeptidase gene. A limited degree of polymorphism was detected with P-9 and P-25, while CP-12 showed a different pattern of bands for each tick isolate. These findings suggest the existence of a complex genotypic diversity of the tick B. microplus population in endemic regions.
Collapse
Affiliation(s)
- D T Passos
- Centro de Biotecnologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
| | | | | | | | | |
Collapse
|
40
|
Baroudi R, Ferreira CA. Contouring the hip and the abdomen. Clin Plast Surg 1996; 23:551-72; discussion 572-3. [PMID: 8906390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
This article describes the surgical procedures used for the aesthetic improvements of the flanks and abdomen. A clinical classification for patient selection regarding when to use liposuction, surgery, or both, is included. Isolated flankplasty, isolated abdominoplasty, and combined flanks with abdominoplasty performed in the same stage are reviewed. Finally, secondary problems after traditional abdominoplasty are evaluated. Solutions are described and illustrated.
Collapse
|
41
|
Brandalise NA, Nagase Y, Ferreira CA. [Mesenteric panniculitis]. Arq Gastroenterol 1980; 17:17-20. [PMID: 7213127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
A case of mesenteric panniculitis is presented in which the main signal was an abdominal pulsable mass and severe obstruction of the lymphatic vessels of the mesentery. A review of the literature was done.
Collapse
|
42
|
Zalmon I, Carvalho G, Ferreira CA. [Induction of ovulation with a new drug: clomiphene citrate]. Hospital (Rio J) 1965; 67:1249-54. [PMID: 5294826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|